Anti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurity - Wikidata - wikimedia - TriplyDB

Anti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurity

Anti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurity

http://www.wikidata.org/entity/Q36752978

about

Erythropoietin in ophthalmology: A literature review Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity Adenosine receptors and caffeine in retinopathy of prematurity.Endoglin promotes angiogenesis in cell- and animal-based models of retinal neovascularization.Modulation of VEGF-induced retinal vascular permeability by peroxisome proliferator-activated receptor-β/δ.Intravitreal injection of bevacizumab for retinopathy of prematurity.Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity Smouldering retinopathy of prematurity: a case treated by multiple antivascular endothelial growth factor therapy.Anti-VEGF therapy in the management of retinopathy of prematurity: what we learn from representative animal models of oxygen-induced retinopathy Short hairpin RNA-mediated knockdown of VEGFA in Müller cells reduces intravitreal neovascularization in a rat model of retinopathy of prematurity.Quantitative analyses of retinal vascular area and density after different methods to reduce VEGF in a rat model of retinopathy of prematurity.Targeting Müller cell-derived VEGF164 to reduce intravitreal neovascularization in the rat model of retinopathy of prematurity.Endothelial NADPH oxidase 4 mediates vascular endothelial growth factor receptor 2-induced intravitreal neovascularization in a rat model of retinopathy of prematurity.Pathophysiology and mechanisms of severe retinopathy of prematurity.VEGFA activates erythropoietin receptor and enhances VEGFR2-mediated pathological angiogenesis Advances in understanding and management of retinopathy of prematurity.Ocular Adverse Effects of Intravitreal Bevacizumab Are Potentiated by Intermittent Hypoxia in a Rat Model of Oxygen-Induced Retinopathy.Targeted Knockdown of Overexpressed VEGFA or VEGF164 in Müller cells maintains retinal function by triggering different signaling mechanisms.Erythropoietin Signaling Increases Choroidal Macrophages and Cytokine Expression, and Exacerbates Choroidal Neovascularization.Quantifying three-dimensional rodent retina vascular development using optical tissue clearing and light-sheet microscopy.

P2860

Q26744850-778CDBF6-14E8-4CC8-B927-C33B830F9A45 Q26772889-E2EAF3BA-DB06-44F5-BB20-E5A259715DDB Q33860622-A90F4B5D-8D52-48A2-8D7F-CC24044C51FC Q34341837-59917CD8-C663-4407-9998-31C6E51FA678 Q34741796-620C5EE8-2411-41CA-B3CB-61E0692AEF75 Q35102460-801B4C96-EB82-4D93-B953-56D2582351BC Q35473907-3E9A1DA8-5FDC-4234-BF31-192A87BDE58D Q36116150-8C71C964-7F0B-441C-87A7-33F1353722C0 Q36379513-A50FA0DF-4A2C-49BA-9BA6-10F31A80FF9D Q37149035-29B0A112-C4DF-4E92-A220-11CFC6023944 Q37561227-4CE360C0-7A27-4084-8B19-C52CB179ABC5 Q37577214-4D2E9E6E-B745-4700-91B1-E8F9C673E058 Q37623450-50036F09-1C39-4539-A3AE-99522CB9C178 Q38274655-2B1E280F-F78D-4BC8-B297-03FC7A8DA03A Q38560836-08C2EF9D-936A-4375-82AF-F41345F903FD Q39052915-4DE44D87-0D19-4A65-A4A5-03B7D5D99FF9 Q41100793-4B109AB8-92F1-40C7-9641-02FB05DA10C6 Q47828029-13E853F4-50EC-4040-BF0B-17EF599736A3 Q48120672-4A5E42FD-C5C2-4E2D-B39C-D58987B72641 Q52573106-806F0837-2AC2-4425-8D1D-C538845DB561

P2860

Anti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurity

http://www.wikidata.org/entity/Q36752978

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Anti-VEGF antibody leads to la ...... of retinopathy of prematurity

@en

type

label

Anti-VEGF antibody leads to la ...... of retinopathy of prematurity

@en

prefLabel

Anti-VEGF antibody leads to la ...... of retinopathy of prematurity

@en

P1433

Q36752978-08B413F6-60D6-4201-B01D-425BC24DD230

P1476

Q36752978-48FC271E-228E-4B5D-9C37-9572DAB0F98F

P2093

Q36752978-075FBE54-1B47-4257-87E3-8F581EB8E46D

Q36752978-2CDB5338-EFCD-483B-8EF0-C821E6CD1B41

Q36752978-4036CF65-DB24-4FEC-9433-B38054C156CB

Q36752978-43933D89-1EF1-49EB-AD04-629B33D329D1

Q36752978-4D2DE002-A8AC-490B-B97D-BEBF56E26BB7

Q36752978-6553DFF5-D0EE-43ED-BA1C-71E868FFA0C0

P2860

Q36752978-03C9D082-0F86-46D3-B787-2F7543F3AED7

Q36752978-04BC5777-E9DA-43D2-82E8-8455CA99CD8E

Q36752978-0D8A4511-35DA-499B-B9AD-9523C9712A3E

Q36752978-309BCBDE-7292-404F-8061-A8781C6069A4

Q36752978-31A415CA-D47A-4F9C-9B2B-23CD05017E77

Q36752978-3542C9C5-9C7F-4F2F-847C-711E734ABBF0

Q36752978-3C02719A-716D-4011-80C7-D36168BE419C

Q36752978-50F1D430-AED0-44C3-93C2-FD23457FAE05

Q36752978-5DC2DBAC-7EFA-4083-A56D-76EC6D63060E

Q36752978-6A41C98E-9E5E-40D5-BF96-CC67475DB2CF

P304

Q36752978-ADF238C3-B9B3-43BE-BEA6-5A17ABA2B1F6

P31

Q36752978-E22E9C02-C9D0-4E32-8273-01500B2B3040

P356

Q36752978-30F984A1-888F-45B4-A99D-1782FB1FB7B2

P407

Q36752978-9C593FC1-AE79-4B99-90BA-99833A0292BE

P433

Q36752978-E2FDA3E2-6170-4C4F-AB67-AB7264A9952C

P478

Q36752978-7CD25C96-8DB3-45E3-A008-C958E1A5D299

P577

Q36752978-C98EC095-59AE-4F2E-8327-FFD54C1EB690

P5875

Q36752978-630A0ABD-824F-4659-B0F4-C0422A85CCB0

P698

Q36752978-5AA9FE19-2D65-4A80-87EA-C551CB1DD18C

P921

Q36752978-54B0A70D-C5E7-4736-AD46-C34772439479

P932

Q36752978-73394959-D20D-4372-90AE-905B46A5BB1D

P356

P1433

Investigative Ophthalmology & Visual Science

P1476

Anti-VEGF antibody leads to la ...... of retinopathy of prematurity

@en

P2093

George Wesley Smith

http://www.w3.org/2001/XMLSchema#string

Haibo Wang

http://www.w3.org/2001/XMLSchema#string

Jeremy Strange

http://www.w3.org/2001/XMLSchema#string

M Elizabeth Hartnett

http://www.w3.org/2001/XMLSchema#string

Manabu McCloskey

http://www.w3.org/2001/XMLSchema#string

Yanchao Jiang

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity

Therapeutic targets in age-related macular disease

Interaction between bevacizumab and murine VEGF-A: a reassessment.

Outcome of eyes developing retinal detachment during the Early Treatment for Retinopathy of Prematurity Study (ETROP).

Human recombinant erythropoietin and the incidence of retinopathy of prematurity: a multiple regression model.

Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy

Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity.

Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity.

Reactivation of retinopathy of prematurity after bevacizumab injection.

An evidence-based meta-analysis of vascular endothelial growth factor inhibition in pediatric retinal diseases: part 1. Retinopathy of prematurity.

P304

2020-2026

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1167/IOVS.13-11625

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235756542

http://www.w3.org/2001/XMLSchema#string

P698

23449716

http://www.w3.org/2001/XMLSchema#string

P921

neovascularization

P932

3621501

http://www.w3.org/2001/XMLSchema#string